Brophy Wealth Management LLC Purchases New Stake in Stryker Co. (NYSE:SYK)

Brophy Wealth Management LLC acquired a new position in shares of Stryker Co. (NYSE:SYK) during the third quarter, Holdings Channel.com reports. The institutional investor acquired 2,844 shares of the medical technology company’s stock, valued at approximately $1,027,000.

Several other large investors also recently added to or reduced their stakes in the stock. Dunhill Financial LLC boosted its position in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Centennial Bank AR raised its stake in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares during the period. Darwin Wealth Management LLC acquired a new position in Stryker in the 3rd quarter valued at about $36,000. HBW Advisory Services LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at approximately $42,000. Finally, Hara Capital LLC acquired a new stake in shares of Stryker during the 3rd quarter worth approximately $42,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,715,540. This represents a 17.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,781 shares of company stock valued at $24,612,275. Insiders own 5.50% of the company’s stock.

Stryker Stock Down 1.0 %

Shares of NYSE SYK opened at $381.04 on Tuesday. The business’s fifty day simple moving average is $371.49 and its 200-day simple moving average is $354.02. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12-month low of $285.79 and a 12-month high of $398.20. The stock has a market cap of $145.26 billion, a P/E ratio of 40.84, a PEG ratio of 2.90 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.46 earnings per share. As a group, equities analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on SYK. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. BTIG Research increased their price target on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Needham & Company LLC boosted their price objective on shares of Stryker from $393.00 to $409.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Royal Bank of Canada upped their target price on shares of Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, Wolfe Research assumed coverage on shares of Stryker in a research report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price target for the company. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $398.40.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.